evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract
4607,GENE_SUMMARY,,"NFE2L2 encodes a transcription factor that regulates critical antioxidant and stress-responsive genes. Aberrant activation of NFE2L2 results in increased proliferation, apoptosis resistance, and resistance to drugs and radiotherapy.",,2017-04-03,,4780,NFE2L2,"nuclear factor, erythroid 2 like 2",True,ENST00000397062,NM_006164.4,NRF2,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4608,GENE_BACKGROUND,,"NFE2L2 (Nuclear factor-erythroid 2-related factor 2), also known as NRF2, is a transcription factor that is important in activating antioxidant proteins to protect against certain environmental and oxidative stresses (PMID: 16968214). Under normal cellular conditions, the interaction of NRF2 with KEAP1 retains the protein in the cytoplasm and promotes its proteasomal degradation via ubiquitination (PMID: 9887101). Upon sensing stress signals, KEAP1 undergoes a conformational change, preventing it from interacting with NRF2 and allowing NRF2 to translocate to the nucleus and drive the expression of specific genes (PMID:12359864). NRF2 can have a protective role in cancer formation from certain chemical carcinogens (PMID: 11248092). However, chronic activation of NRF2 can also support the development of chemo- and radio-resistance (PMID: 24142871). Tumor-associated NRF2 activation can result from inactivation of KEAP1 through mutation, loss of heterozygosity or epigenetic silencing (PMID: 19321346). NRF2 activation can also arise directly from mutations in NFE2L2 in the KEAP1-binding domains (PMID: 18757741, 19967722).",,2017-10-19,,4780,NFE2L2,"nuclear factor, erythroid 2 like 2",True,ENST00000397062,NM_006164.4,NRF2,False,18757741,Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.,Proceedings of the National Academy of Sciences of the United States of America,2018-09-09T20:08:00,105,36,13568-73,Shibata T et al,doi: 10.1073/pnas.0806268105,,0001-09-09,,16968214,Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway.,Annual review of pharmacology and toxicology,2007,47,,89-116,Kensler TW et al,,,Kensler TW et al. Annual review of pharmacology and toxicology. 2007;47()89-116.,,9887101,Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.,Genes &amp; development,0001-01-01,13,True,76-86,Itoh K et al,,,0001-01-01,,12359864,Regulatory mechanisms controlling gene expression mediated by the antioxidant response element.,Annual review of pharmacology and toxicology,2003,43,,233-60,Nguyen T et al,,,Nguyen T et al. Annual review of pharmacology and toxicology. 2003;43()233-60.,,19967722,Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.,The Journal of pathology,2018-03-01T20:10:00,220,4,446-51,Kim YR et al,doi: 10.1002/path.2653,,0001-03-01,,24142871,The emerging role of the Nrf2-Keap1 signaling pathway in cancer.,Genes &amp; development,2018-10-15T20:13:00,27,20,2179-91,Jaramillo MC et al,doi: 10.1101/gad.225680.113,,0001-10-15,,19321346,NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.,Trends in biochemical sciences,2018-04-01T20:09:00,34,4,176-88,Hayes JD et al,doi: 10.1016/j.tibs.2008.12.008,,0001-04-01,,11248092,Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice.,Proceedings of the National Academy of Sciences of the United States of America,2018-03-13T20:01:00,98,6,3410-5,Ramos-Gomez M et al,,,0001-03-13,
